LADAN HAKIMJAVADI: Open Payments
NPI 1144849415 · CHARLESTOWN, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$909 in 35 payments from 10 companies in 2025. Trend: 2023 $542 · 2024 $814 · 2025 $909
Food & beverage: $909
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 11 | $291 |
| AstraZeneca Pharmaceuticals LP | 6 | $207 |
| PFIZER INC. | 3 | $71 |
| Amgen Inc. | 3 | $70 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $65 |
| Novartis Pharmaceuticals Corporation | 3 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic, Inc. | 1 | $22 |
Products named: VERQUVO, LOKELMA, Repatha, Kerendia, LEQVIO, FARXIGA, AMVUTTRA, VYNDAQEL.
Industry payments across MA — which companies pay providers there.
